Zurcher Kantonalbank (Zurich Cantonalbank) Avadel Pharmaceuticals PLC Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 25, 2024	SELL	$12.55 - $17.22 $24,911 - $34,181	-1,985 Reduced 99.05%	19 $0
Q4 2023 Jan 30, 2024	SELL	$9.64 - $14.59 $2,371 - $3,589	-246 Reduced 10.93%	2,004 $28,000
Q3 2023 Oct 25, 2023	SELL	$10.3 - $15.99 $7,622 - $11,832	-740 Reduced 24.75%	2,250 $23,000
Q2 2023 Aug 07, 2023	SELL	$8.48 - $16.48 $4,528 - $8,800	-534 Reduced 15.15%	2,990 $49,000
Q1 2023 May 08, 2023	BUY	$6.41 - $9.95 $3,628 - $5,631	566 Added 19.13%	3,524 $32,000
Q4 2022 Feb 01, 2023	SELL	$5.02 - $10.0 $2,816 - $5,610	-561 Reduced 15.94%	2,958 $21,000
Q3 2022 Nov 09, 2022	SELL	$2.57 - $7.31 $814 - $2,317	-317 Reduced 8.26%	3,519 $18,000
Q1 2022 Apr 21, 2022	BUY	$5.46 - $8.29 $20,944 - $31,800	3,836 New	3,836 $26,000

Others Institutions Holding AVDL

# of Institutions

Shares Held

1.07M

Call Options Held

Put Options Held

View Full List

About AVADEL PHARMACEUTICALS PLC

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

More about AVDL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account